Format

Send to

Choose Destination
Crohns Colitis 360. 2019 Oct;1(3):otz026. doi: 10.1093/crocol/otz026. Epub 2019 Aug 19.

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab.

Author information

1
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Abstract

Background:

We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse.

Methods:

Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome.

Results:

The median OSM in biochemical responders was 86 (69-148) pg/mL compared with 166 (74-1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011).

Conclusions:

Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.

KEYWORDS:

Crohn disease; biomarkers; companion diagnostic; neutrophil CD64; pediatric

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center